Assessment of DHA On Reducing Early Preterm Birth

PHASE3CompletedINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

June 8, 2016

Primary Completion Date

October 5, 2020

Study Completion Date

October 5, 2020

Conditions
Preterm Birth
Interventions
DRUG

Docosahexaenoic acid - 800mg/day

All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)

DRUG

Docosahexaenoic acid - 200mg/day

The control group will receive 1-capsule containing 200 mg DHA/d.

OTHER

Placebo

Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.

Trial Locations (3)

43210

Ohio State University, Columbus

45220

University of Cincinnati, Cincinnati

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

University of Cincinnati

OTHER

collaborator

Ohio State University

OTHER

collaborator

Nationwide Children's Hospital

OTHER

lead

University of Kansas Medical Center

OTHER

NCT02626299 - Assessment of DHA On Reducing Early Preterm Birth | Biotech Hunter | Biotech Hunter